UK markets closed
  • NIKKEI 225

    26,402.84
    -508.36 (-1.89%)
     
  • HANG SENG

    20,120.68
    -523.60 (-2.54%)
     
  • CRUDE OIL

    111.44
    -0.77 (-0.69%)
     
  • GOLD FUTURES

    1,840.10
    -1.10 (-0.06%)
     
  • DOW

    31,253.13
    -236.94 (-0.75%)
     
  • BTC-GBP

    24,189.08
    +737.55 (+3.15%)
     
  • CMC Crypto 200

    669.81
    +17.58 (+2.69%)
     
  • ^IXIC

    11,388.50
    -29.66 (-0.26%)
     
  • ^FTAS

    4,038.94
    -71.55 (-1.74%)
     

Vistin Pharma ASA: Annual Report for 2021

  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Vistin Pharma ASA
Vistin Pharma ASA

Oslo, Norway, 27 April 2022

Please find attached the Annual Report for 2021 for Vistin Pharma ASA. There are no material changes in the financial statements compared to the preliminary full year result presented on 17 February 2022.

The annual report for 2021 will also be made available on www.vistin.com.

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

*****

For further information, please contact:

Alexander Karlsen
CFO
+47 97 05 36 21
Alexander.karlsen@vistin.com


About Vistin Pharma | www.vistin.com

Vistin Pharma is a Norwegian pharmaceutical company producing Metformin Hydrochloride (API). The Metformin is also available as Direct Compressible lubricated granules. As a solely dedicated European Metformin producer, Vistin Pharma is a well-positioned supplier to leading pharmaceutical companies. Vistin Pharma is headquartered in Oslo, Norway, and has highly qualified employees and a dedicated manufacturing facility in Kragerø.


Attachments


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting